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A B S T R A C T
The European Partnership for Alternative Approaches to Animal Testing (EPAA) convened a ‘Blue Sky Workshop’
on new ideas for non-animal approaches to predict repeated-dose systemic toxicity. The aim of the Workshop
was to formulate strategic ideas to improve and increase the applicability, implementation and acceptance of
modern non-animal methods to determine systemic toxicity. The Workshop concluded that good progress is
being made to assess repeated dose toxicity without animals taking advantage of existing knowledge in tox-
icology, thresholds of toxicological concern, adverse outcome pathways and read-across workflows. These ap-
proaches can be supported by New Approach Methodologies (NAMs) utilising modern molecular technologies
and computational methods. Recommendations from the Workshop were based around the needs for better
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chemical safety assessment: how to strengthen the evidence base for decision making; to develop, standardise
and harmonise NAMs for human toxicity; and the improvement in the applicability and acceptance of novel
techniques. “Disruptive thinking” is required to reconsider chemical legislation, validation of NAMs and the
opportunities to move away from reliance on animal tests. Case study practices and data sharing, ensuring
reproducibility of NAMs, were viewed as crucial to the improvement of non-animal test approaches for systemic
toxicity.
1. Introduction
This report describes the main findings and conclusions of The
European Partnership for Alternative Approaches to Animal Testing
(EPAA) ‘Blue Sky Workshop’ which discussed new ideas for the use of
non-animal approaches in the assessment of repeated-dose systemic
toxicity, held on 1–2 October 2019 in Brussels, Belgium. The EPAA
‘Blue Sky Workshop’ aimed to formulate strategic research elements
and derive a list of recommended actions to bring innovative ap-
proaches forward for repeated-dose systemic toxicity (RDT). The
Workshop built upon various initiatives including two previous
Workshops for RDT organised by the EPPA. In 2008 an EPAA Workshop
pioneered ideas for systemic toxicity research by combining computa-
tional chemistry, systems biology and toxicology (Kimber et al., 2011).
The ideas from this Workshop stimulated research in the European
“Safety Evaluation Ultimately Replacing Animal Testing” (SEURAT-1)
cluster of projects from 2011 to 2015 (Gocht et al., 2015) and latterly
Cosmetics Europe's Long Range Research Strategy (LRSS) (Desprez
et al., 2018) and the EU-ToxRisk Project. A second EPAA Workshop in
2018 was devoted to finding cross-sector synergies in using alternatives
for RDT testing to provide non-animal solutions relating to chemical
safety assessment. The Workshop concluded that there are no validated
alternatives to RDT and that a direct one-to-one replacement is not
appropriate (Laroche et al., 2019).
The EPAA Partners' Forum brought together over 30 participants
from industry and the European Commission (EC), along with invited
representatives from regulatory agencies and researchers from aca-
demia. The invited participants represented the EC Directorates-
General (DGs) Environment (ENV); Internal Market, Industry,
Entrepreneurship and SMEs (GROW); Joint Research Centre (JRC); and
Research and Innovation (RTD); the European Chemicals Agency
(ECHA); the European Food Safety Authority (EFSA); the U.S.
Environmental Protection Agency; as well as companies from the che-
micals, pharmaceuticals, cosmetics, soaps and detergents, fragrance
and crop protection industries and their European trade associations; in
addition to representatives from key EC funded projects relevant for
this topic. Drs George Daston and Catherine Mahony co-chaired the
‘Blue Sky Workshop’ and moderated the discussions.
It should be noted that this report is based on short presentations
and actual discussions at the EPAA ‘Blue Sky Workshop’ aiming to
achieve the stated objectives of the event. These focussed on the
practical issues of developing acceptable non-animal approaches for
assessing repeated-dose systemic toxicity. This report should not be
considered a complete or comprehensive review of research efforts in
the area of alternatives to testing for repeated-dose systemic toxicity
nor a detailed record of all discussions held, but rather a reflection on
the strategic ideas that emerged to push the science forward and in-
crease the pace of uptake.
1.1. Background
Systemic effects following repeated exposure to chemicals remain
difficult to determine and have traditionally involved the use of whole
animal testing in vertebrate species. There is an opportunity and desire
for change across all industrial sectors and stakeholders to a more ro-
bust and human-relevant means of determining adverse outcomes, al-
though a number of significant challenges have to be overcome to
achieve this goal. Whilst significant progress has been made in recent
years, it is acknowledged that a direct one-to-one replacement of the
currently applied in vivo animal tests is not possible, nor necessarily
desirable, and that integrated use of new technologies and approaches
is more likely to succeed (Laroche et al., 2019; Thomas et al., 2019).
In order to understand some of the challenges and relatively slow
rate of change in chemical safety assessment, a number of factors must
be considered. The general aim of legislation to regulate chemicals is to
protect human health and the environment whilst allowing for efficient
and effective functioning of trade. Whereas legislation is intended to
recognise the need for innovation, competitiveness and sustainability, it
is often written such that changes in how safety may be evaluated, such
as through implementation of New Approach Methodologies (NAMs)
(defined in Section 2), are difficult. Within the European Union (EU)
alone there are over 40 pieces of key chemical legislation, crossing all
industrial sectors (Laroche et al., 2019). The Workshop recognised that
there are no validated/standard alternative methods for RDT, although
many NAM-based approaches are currently under development and/or
evaluation. In addition, there are number of factors responsible for the
relatively slow rate of change in regulatory acceptance of updates to
RDT testing and implementing new technology and innovations. In
many sectors the lack of validated methods for RDT means there is
reliance on the traditional testing paradigm, this is, in part, due to the
slow pace of validation and acceptance of NAMs. There has been a lack
of agreement, from all sides, to consider in silico or in vitro techniques
which are not fully validated and approved by the Organisation for
Economic Co-operation and Development (OECD). There is also a lack
of knowledge to handle and interpret new data sets, e.g. from omics
technologies, amongst many “traditional” toxicology researchers. The
situation of using data from the new technologies is exacerbated by a
lack of coherent and transferable data resources to use the new in-
formation. In addition to issues over validation of NAMs, there is also a
lack of harmonisation and consistency in data requirements in regula-
tions between sectors and also between regions. All of these factors, and
others, have resulted in the varied and limited implementation of new
RDT methods in regulatory toxicology.
The Threshold of Toxicological Concern (TTC) and read-across ap-
proaches are well established. Various initiatives have demonstrated
their applicability and how NAMs could be used to augment read-
across. Notable amongst these (with particular reference to the cos-
metics sector) were the European Union/Cosmetics Europe SEURAT-1
initiative which provided a workflow for assessing RDT (Gocht et al.,
2015), taking account of low exposure through the TTC (Yang et al.,
2017) as well as laying the groundwork for ab initio next generation risk
assessment (NGRA) (Berggren et al., 2017). This led to the conception
of principles for NGRA for cosmetics by a working group of the Inter-
national Cooperation on Cosmetics Regulation (ICCR) (Dent et al.,
2018). Both the workflow and the principles have been taken up in the
Cosmetics Europe LRSS (Desprez et al., 2018) where, in partnership
with the EU-ToxRisk Project, they are being used to support the cap-
ability to make decisions through read-across and from ab initio
schemes. Currently the latter are being explored using in vitro bioac-
tivity from high throughput and high content data streams as a surro-
gate Point of Departure (PoD) for comparison to exposure predictions
(Paul Friedman et al., 2020; Pham et al., 2019). This is proving to be a
useful tool for the prioritisation of substances where the bioactivity and
exposure overlap but it is noted that the in vitro POD currently does not
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equate to adverse effects due to the upstream nature of the molecular
targets, short term duration and limited biological space of the in vitro
platforms such as ToxCast. As well as progress in the science and
technology, and development of workflows and principles, the Work-
shop recognised from previous and on-going work the importance of
illustrating the value of NAMs through successful case studies. In this
regard, the decision context in the new paradigm is essential as this puts
conditions and constraints on the ‘why, what, how and who’, for ex-
ample working in an emergency response situation, versus a controlled
exposure in humans or ingredient stewardship versus registration of a
new substance or drug. There are also gaps in our knowledge and the
ultimate replacement of an animal test will need to ensure not only
sufficient coverage of toxicological modes of action, but also
appropriate consideration of toxicokinetics and metabolism and
temporal aspects as well as aspirational aspects such as including
population variability.
1.2. Aim of workshop: questions to be answered
In the context of the current state-of-the-art of chemical safety as-
sessment, the Workshop participants were requested to formulate
strategic ideas that would help improve and increase the applicability,
implementation, familiarisation and acceptance of modern non-animal
methods to determine systemic toxicity. Specifically, the following
questions were addressed:
• How can the “modern safety assessment toolbox” (see
Supplementary Information Table 1) be better utilised in chemical
safety assessments?
• What is needed to make chemical safety assessments less reliant on
animal data and more relevant to human health?
• What are the different ways of thinking required to implement the
new methods and make them acceptable for all stakeholders?
The Workshop also aimed to build on previous EPAA Workshops
(e.g. Kimber et al., 2011; Laroche et al., 2019) to find solutions pro-
viding information relating to chemical safety assessment. There was a
particular emphasis on the need to make assessment more efficient in
terms of costs, time and resources as well as making the solution more
relevant to human safety. Specifically, the focus of the Workshop was
on NAMs that can provide information that may be relevant to assessing
RDT and/or human safety; the use of NAMs to derive PoDs for human
safety assessments; strategies to use and combine synergistically the
information and knowledge from NAMs and how to incentivise these;
and means to implement the information from NAMs such that it may,
ultimately, be acceptable for global, harmonised regulatory purposes.
To assist in these goals, the Workshop considered a nominal “toolbox”
for modern chemical safety assessment that comprised NAMs and
strategies for implementation, the approaches are summarised below
and in Supplementary Information Table S1.
In order to address these themes, the Workshop was organised into
plenary presentations and discussions as well as breakout groups ad-
dressing specific questions. This report summarises the key delibera-
tions in the Workshop, specifically the NAMs that could be applied
(summarised in Section 2) as well as the strategies and workflows for
their use (summarised in Section 3), the challenges and opportunities
for the implementation of the NAMs (Section 4), as well as making
recommendations for the way forward towards a new era of assessing
systemic toxicity using NAMs (Section 6).
2. Brief overview of the state-of-the-art of current technologies
including computational techniques and other new approach
methodologies (NAMs)
The Workshop discussed the technologies that can be currently used
in chemical safety assessment. The new technologies are described
under the broad umbrella of NAMs. The term ‘new approach meth-
odologies’ (NAMs) has been recently adopted in reference to any non-
animal technology, methodology, approach, or combination thereof
that can be used to provide information on chemical hazard and risk
assessment that avoids the use of intact animals (US EPA, 2018). Par-
ticipants were provided with illustrations of various types of NAMs, as
summarised in Supplementary Information Table S1 and below. The
Workshop was not able to undertake a full review of NAMs for chemical
safety, rather it selected illustrative examples, and analysed the chal-
lenges and potential solutions for their implementation. This section
provides an overview of the types of NAMs that may be considered –
along with examples presented in the Workshop. Challenges and solu-
tions to their use and implementation are provided in Section 4.
2.1. Computational chemistry and in silico approaches
A variety of computational chemistry and in silico approaches that
can be used to make predictions of hazard, kinetics and exposure were
noted in the Workshop. These range from the well-established use of
structural alerts, (quantitative) structure-activity relationships ((Q)
SARs), and read-across (described in more detail in Section 3.2) to in-
novative approaches.
The Workshop noted that computational models are moving into a
new era, extending what has been previously undertaken in (Q)SAR.
This trend can be thought of as moving from predominantly 2D models
to those being in 3D. The advantage of 3D models is the ability to model
protein binding and interactions, for instance, a recent review has de-
monstrated the utility of artificial intelligence, through machine
Abbreviations
AOP Adverse Outcome Pathway
EC European Commission
ECHA European Chemicals Agency
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EPA United States Environmental Protection Agency
EPAA European Partnership for Alternative Approaches to
Animal Testing
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FAIR Findable, Accessible, Interoperable, and Reusable
HTS High Throughput Screening
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KERs Key Event Relationships
KEs Key Events
LRSS Long Range Science Strategy
MIE Molecular Initiating Event
MPS Microphysiological Systems
MoA Mode of Action
NAMs New Approach Methodologies
NGRA Next Generation Risk Assessment
OCM Organotypic Culture Model
OECD Organisation for Economic Co-operation and Development
PoD(s) Point(s) of Departure
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learning, to model hormone receptor binding affinity (Wong et al.,
2017).
2.2. Computational systems biology
Biological systems are complex, with many interacting parts in
multiscale networks that ultimately determine how cells and tissues
react to genomic programming and biomolecular perturbations. In silico
approaches have been extended to develop computational systems
biology and systems pharmacology models. These attempt to resolve
the challenge of translating complex data into predictive models re-
levant to humans (Saili et al., 2019).
2.3. In vitro and systems level models
The Workshop acknowledged the potential role in chemical safety
assessment of non-animal (in vitro) test methods ranging from relatively
simple cellular systems up to more complex systems reflecting the de-
velopment and function of tissues and, potentially, organs. Their con-
tribution was seen to relate to aspects of chemical safety such as me-
chanisms of action and describing and quantifying key events.
Particular focus was paid to organoids, which are part of the growing
field of microphysiological systems (MPS) that also includes Organ-on-
Chips. MPS models recapitulate the underlying biology and toxicology
of key events in (Adverse Outcome Pathways) AOPs. There has been a
growth in such systems for various organs which could assist in the
provision of information relevant to chemical safety assessment (Marti-
Figueroa and Ashton, 2017). However, the Workshop recognised that
whilst spontaneous organoid morphogenesis has the capability of pro-
ducing significant microscale organisation and cell phenotype diversi-
fication, it is often inconsistent and non-stereotyped at the macroscale
with regard to cell phenotype composition, tissue morphology and
tissue structure, anatomy and cytoarchitecture. There is also a need for
even better mimicking of physiological conditions i.e. advanced mi-
crofluidics, combined with real-time monitoring of toxicity read-outs.
Such limitations need to be defined and understood for their application
to alternative, more public health relevant and efficient, chemical
toxicity testing methods. As such, there is a need for reproducibility in
organoids to increase confidence and reduce the cost of screening as-
says.
2.4. Omics technologies and complex data
The Workshop agreed that there was already a demonstrable value
to omics (and consequently high dimensional data) in toxicology, which
could assist in chemical safety assessment. Such high dimensional, or
complex, data are derived from a number of sources such as tox-
icogenomics or high throughput screening (HTS) from ToxCast.
Different types of data have different characteristics and will require
translation in practical solutions. The data provided by omics can
provide considerable biological coverage and consequently insights in
MOA directly or allowing for hypothesis generation. Omics and big data
are one key area where data sharing will be vital and should build on
existing resources. As part of this, progress is being made in the inter-
operability of big data resources (Watford et al., 2019) and reporting
standards (Viant et al., 2019).
The Workshop agreed that new methods in omics technologies
could have distinct benefits and provide useful information for che-
mical safety assessment whilst acknowledging that current short-
comings in omics technologies inhibit progress.
3. Making a decision from NAMs data – strategies to integrate and
apply information
The NAMs described in Section 2 will provide the raw data or in-
formation about the hazard or exposure to a chemical. In order to make
a decision regarding the safety of a chemical in a particular exposure
scenario the Workshop acknowledged the requirement for frameworks
or workflows to organise and integrate the data and apply a weight-of-
evidence. Thus, it is not anticipated that an individual NAM will replace
an in vivo assay for a complex toxicological endpoint, rather a combi-
nation of data and approaches is foreseen to build consensus with an
appropriate, stated, level of certainty (Laroche et al., 2019). For in-
stance, the ICCR principles could act as a guide for further development
of integrate workflows for risk assessment.
This section brings together the types of approaches discussed in the
Workshop that can be used to combine information and data from
NAMs such that a risk assessor and/or risk manager could make a de-
cision.
3.1. Mechanistic understanding and organisation within Mode of Action
ontologies
The Workshop agreed that for the successful use of NAMs for che-
mical safety assessment, there is a requirement for mechanistic under-
standing and the meaning of data derived from NAMs. In the context of
the uncertainty associated with mechanisms of action, this can be ra-
tionalised in terms of AOPs whereby there is often much information on
the molecular initiating event (MIE) e.g. from QSAR, high-throughput
screening and toxicogenomics, as well as many historical data on the
adverse outcome. However, much less is known – and hence there is
much greater uncertainty - about the intermediate key events (KEs) and
key event relationships (KERs) for many AOPs. The use of mechanistic
in vitro models as part of a predictive toxicology workflow is under-
pinned by the report from the National Academy of Science (National
Academies of Sciences, Engineering, and Medicine, 2017) and includes
global gene expression, high throughput screening, as well as bioin-
formatic and biophysical approaches – a simplified workflow adapted
from the National Academy of Sciences report is shown in Fig. 1. Such
information can support the identification of relevant analogues for
read-across (discussed in Section 3.2). Whilst much is known regarding
mechanisms of action for some endpoints, there are still many un-
knowns. One solution will be a concerted effort to map mechanisms of
toxicity. In cases where insufficient mechanistic information or
knowledge is available, e.g. for new chemistries, techniques such as
agent-based computational models, the range of in vitro systems from
Fig. 1. A simplified workflow for predictive tox-
icology adapted from the National Academy of
Science (National Academies of Sciences,
Engineering, and Medicine, 2017). The workflow
allows for identification of suitable analogues for a
target chemical and integration of toxicokinetic
data to establish an acceptable level of exposure, or
the incorporation of NAMs data to support the de-
cision.
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simple functional assays to organotypic culture models and MPS may
provide outputs to demonstrate similarity with known compounds. The
integration of systems biology approaches with such models and assays
will ultimately facilitate elucidation of the necessary mechanistic in-
sights.
In addition to the protective nature (to human health) of bioactivity
based assessments, there is an increasing realisation that information
relating to mode-of-action can be captured within a framework, or
ontology, to make it useable for chemical safety assessment. Recent and
on-going work relating to Mode of Action (MOA) Ontologies has been
funded through the Cosmetics Europe LRSS (Desprez et al., 2019).
Thus, the integration of mechanistic information into predictive
toxicology workflows, along with knowledge of exposure and bioki-
netics, is considered one of the cornerstones of modern chemical safety
assessment. Key to the use of this information is the appreciation of the
contribution of bioactivity based assessments that are designed to be
protective of human health.
3.2. Read-across
Read-across is the process by which the toxicity of a compound (the
target compound) with no, or insufficient, data is read across from one
with high quality data (the source compound(s)) (Berggren et al.,
2015). The Workshop participants agreed that read-across is a key
technique to predict the hazard of some substances and is being
transformed through a better understanding of uncertainties and in-
clusion of NAM and other data. This process has gained some, but not
universal, acceptance for regulatory and other purposes. Key to un-
derstanding the use of read-across and its acceptance is definition of the
uncertainties in the process (Schultz et al., 2019). In addition, it is
foreseen that read-across will develop in a number of ways:
- “traditional” read-across, the current analogue based approach fo-
cussed on hazard;
- “next-generation” read-across, with an increased input of NAM data,
for instance to support the read-across hypothesis and provide evi-
dence of toxicodynamic similarity. In certain circumstances, this
may also include exposure based information to assist in making a
decision regarding risk;
- “functional” read-across, when chemistry-based analogues may not
be appropriate or available and the similarity concept is refined with
biological or mechanistic information (this may also be referred to
as “biological” read-across in some circumstances).
NAMs data can assist in all read-across approaches in the building
up of lines of evidence to support an overall weight-of-evidence. These
different read-across approaches should not be seen as mutually ex-
clusive. It is likely that both functional and next-generation read-across
will build on the traditional approaches. The opportunity is to develop
these techniques so that they resolve current issues, such as the
justification of similarity and read-across hypotheses. NAMs may also
support further and better category formation i.e. development of
groups of chemicals supported by NAMs data.
Read-across is increasingly becoming a data gathering and pre-
dictive exercise. As such, better and more easily accessible computa-
tional tools are required. These range from well curated chemical and
biological databases, to chemoinformatic workflows capable of com-
bining multiple sources of information.
3.3. Ab initio
Ab initio methods are necessary when there are no existing data
and/or TTC or read-across is not possible for the chemical in question.
Berggren et al. (2017) described an ab initio assessment in terms of a
safety evaluation being performed on the basis of hypothesis-driven in
vitro testing combined with in vitro to in vivo extrapolation by
computational modelling. Further, Berggren et al. (2017) demonstrated
the application of an ab initio approach as part of a workflow including
TTC and read-across. In the absence of information from animal tests,
data from NAMs will be relied upon to make a decision. These ap-
proaches, typified by Berggren et al. (2017), allow for a consideration
of both dose and bioactivity – as such they require appropriate in-
formation to inform on these topics. This information may come from
appropriate NAMs. The ab initio process is seen as being flexible and
transparent. In many ways it can incorporate the current Inte-
grated Approaches for Testing and Assessment (IATA) paradigm as it
allows the decision maker to go further through the inclusion of ex-
posure and dose.
4. Key opportunities, challenges and solutions to improving the
assessment of systemic toxicity
The Workshop identified a number of key opportunities and chal-
lenges to the implementation of new technologies to chemical safety as
well as potential solutions. These covered all aspects of the topics dis-
cussed in the Workshop and can be summarised as being relating to the
following:
- Problem formulation: The current paradigm for chemical safety
assessment has changed little for several decades. With the new
technologies available, there is an opportunity to redefine how we
pose the risk assessment or regulatory problem in ways that com-
plement the tools we have at our disposal to answer them in the
context of our protection goals.
- Legislation: Global chemical safety legislation is complex and
varied, as well as allowing and/or encouraging only minor appli-
cation of new technologies, as a result of current need for, and re-
strictions of, validation of NAMs. There is an opportunity to rethink
the current legislative process, ensuring it is sufficiently con-
servative, to make it appropriate for the new technologies and
problem formulation.
- Data sharing: Data sharing is fundamental across all technologies
and approaches. Currently data sharing is incomplete, or even
lacking, for many types of toxicological data and information. The
opportunity is to increase the availability of data for sharing with
authorities but also within industries and to implement appropriate
technologies and informatics structures, doing so applying the
Findable, Accessible, Interoperable, and Reusable (FAIR) principles
(Wilkinson et al., 2016). A globally and freely accessible database is
desirable, and free sharing of data should be incentivised. Solutions
need to be identified to enable more extensive sharing of propriety/
confidential data.
- Development of computational approaches and other NAMs: There
are many in silico models and other NAMs for use in safety
assessment. These are at various stages of development, validation
and acceptance. The opportunity is to establish which approaches
are currently suitable to chemical safety assessment and, for those
not at that stage, to establish how to develop promising methods
further.
- Development of decision-making frameworks: Read-across, ab initio
approaches and IATA are frameworks to enable chemical safety
decisions, at different stages of maturity. The opportunity is to de-
velop one or more decision making frameworks that reflect the new
technologies to an acceptable level.
- Acceptance of in silico approaches, other NAMs and Next Generation
Risk Assessment (NGRA). The acceptance of new methods and de-
cision-making frameworks is complex and variable. The opportunity
is to revise how validation can be achieved and to improve the ac-
ceptance of non-animal methods. To improve acceptance, a ‘safe
harbour concept’ may be helpful, where safety assessments based on
NAMs are shared alongside typical regulatory submissions.
- Communication. Communication between stakeholders has
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traditionally been poor, although better dialogue is now occurring
between the regulated community and regulators. However, the
general public remains sceptical of industry. The opportunity is to
engage more fully across all stakeholders, including consumers, to
transparently discuss how the new approaches could provide better
and more relevant chemical safety assessment.
The Workshop participants acknowledged that there is no single
solution to improving chemical safety assessment and to incorporating
the new technologies in an appropriate legislative, decision-making
framework. Effort to improve chemical safety assessment should not be
considered in isolation within the topics listed in this section but should
cross them. The development of case studies, which include all stake-
holders and cross sectors, is seen as one crucial means of achieving this
goal.
There were a large number of individual challenges and potential
solutions identified by the Workshop to the improvement of chemical
safety assessment. These are organised and summarised in the text
below and provided in more detail in Supplementary Information Table
S2.
5. Conclusions
The EPAA Blue Sky Workshop ‘New Ideas for Systemic Toxicity’ re-
cognised that we have collectively been on the right track in our ap-
proach to assessing RDT without animals. Previous EPAA Workshops
(Kimber et al., 2011; Laroche et al., 2019), as well as other initiatives
(e.g. SEURAT-1, LRSS, EU-ToxRisk amongst others), acknowledged and
utilised existing knowledge in toxicology, including read-across work-
flows that build upon historical toxicology testing data supported by
modern molecular and computational methods to develop the next
generation of safety assessment. TTC is probably the most predominant
example of non-animal approaches in safety assessment that has gained
broad regulatory acceptance. The Workshop participants concluded
that there are many opportunities to use all NAMs to address challenges
in toxicology and risk assessment. However, using these approaches
will require the systematic understanding and solving of technical and
data analysis challenges, if such approaches are ever to reach broader
acceptance. A wide range of tools and means to implement them will be
required, spanning all possible toxicological modes of action from tar-
geted testing to untargeted comprehensive testing. Currently grouping
and read-across is relied upon in many contexts and can be developed
further to include biological (functional) and exposure information. Ab
initio approaches can be applied when read-across and in silico tools are
not sufficient, but will require substantially more work. These will
eventually lead to integrative systems modelling and the transition
from decisions based mainly on in vivo data to human knowledge-driven
decisions. Improvements will be made through both evolution of
knowledge and tools, but also revolution in their application, under-
standing and dissemination. Key to this will be ensuring the new ap-
proaches are transparent (and mechanistically-based), reproducible,
accessible (encouraging all aspects of data sharing) and in line with the
desired protection goal. Partnering with regulators to achieve appro-
priate problem formulation, transformation of current regulations and
implementation of alternatives in tiered strategies building confidence
with the inclusion of further data and information will be crucial. This
could be made possible through the use of case studies and will increase
confidence and accelerate their application to chemical risk assessment.
6. Recommendations
It was emphasised that more could be made of biological similarity
as the basis to form chemical groups for read-across and a move to-
wards ab initio assessment would probably require disruptive regulatory
approaches. Having said that, the regulatory agencies present were
already using TTC and read-across under certain circumstances and
were generally supportive of the use of NAMs, especially when they
support read-across. It is acknowledged that bioactivity based
assessment is generally conservative and this may be crucial for risk
assessment.
There are many areas of technology that are already being devel-
oped where more work is needed. These include:
• A deep mechanistic understanding of systems toxicology, linked to
human relevant toxicological outcomes, to develop a full range of
computational and in vitro methods.
- This would include the development of databases that use ontol-
ogies of modes of action that catalogue the known universe of
MOAs, so that the degree of biological coverage needed by NAMs
can be estimated and to structure the development of AOPs.
• Chemistry/biochemistry
- Identify 3D structural features that better inform read-across and
are the basis for QSARs.
- Better predictions of physico-chemical characteristics and their
relationship to toxicokinetic parameters.
• Omics assays
- To gain insights into broad cellular and molecular mechanistic
changes across different cells and tissues from chemical pertur-
bations as a means to maximise coverage of biological space, as
support for read-across and the basis for functional read-across as
well as providing PoDs.
• Systems-level models
- Microphysiological systems to associate mechanistic changes with
predictions of adverse outcome within and across different target
organs.
- Computational systems – to associate mathematically the con-
nections between molecular and cellular perturbations and ad-
verse outcome.
In addition to basic scientific research, there were policy
recommendations to facilitate progress:
• The provision of opportunities for regulators to find ways of
accepting the new generation of risk assessment processes and to
explore mechanisms beyond traditional validation. Specifically, the
new bioactivity assays are known to be protective and conservative
and methods to define this and drive acceptance are required to
increase uptake.
• Deliberate targeting of data sharing and case studies practices, re-
warding those with a will to share data and move towards appli-
cation of non-animal methods. The regulatory processes could be
used to mobilise and direct resources towards those cases where
there is the will to use non-animal data.
• Risk managers should conduct a ‘stock take’ of problem formula-
tions and protection goals. This should identify strengths and
weaknesses in current risk management practices and opportunities
to move away from reliance on animal tests.
• Harmonisation of performance standards and reference standards.
• The need for a road map on how to transform NAM development
into regulatory decision-making, and the resources (e.g. public
funds) to do this.
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